187 related articles for article (PubMed ID: 20425387)
1. Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.
Silver RT
Curr Hematol Malig Rep; 2007 Feb; 2(1):43-6. PubMed ID: 20425387
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
Silver RT
Curr Hematol Rep; 2005 May; 4(3):235-7. PubMed ID: 15865878
[TBL] [Abstract][Full Text] [Related]
3. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
Merx K; Fabarius A; Erben P; Griesshammer M; Reiter A; Hofmann WK; Hehlmann R; Hochhaus A; Lengfelder E
Ann Hematol; 2013 Jul; 92(7):907-15. PubMed ID: 23525684
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
Nussenzveig RH; Cortes J; Sever M; Quintás-Cardama A; Ault P; Manshouri T; Bueso-Ramos C; Prchal JT; Kantarjian H; Verstovsek S
Int J Hematol; 2009 Jul; 90(1):58-63. PubMed ID: 19484334
[TBL] [Abstract][Full Text] [Related]
5. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
Jones AV; Silver RT; Waghorn K; Curtis C; Kreil S; Zoi K; Hochhaus A; Oscier D; Metzgeroth G; Lengfelder E; Reiter A; Chase AJ; Cross NC
Blood; 2006 Apr; 107(8):3339-41. PubMed ID: 16352805
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera responds to imatinib mesylate.
Jones CM; Dickinson TM
Am J Med Sci; 2003 Mar; 325(3):149-52. PubMed ID: 12640290
[TBL] [Abstract][Full Text] [Related]
7. Phase II open label trial of imatinib in polycythemia rubra vera.
Jones CM; Dickinson TM; Salvado A
Int J Hematol; 2008 Dec; 88(5):489-494. PubMed ID: 19009241
[TBL] [Abstract][Full Text] [Related]
8. [Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].
Jomen W; Kuroda H; Matsuno T; Sato M; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Kato J; Nojiri S
Rinsho Ketsueki; 2014 Mar; 55(3):360-5. PubMed ID: 24681942
[TBL] [Abstract][Full Text] [Related]
9. [Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy].
Marie I; Hervé F
Rev Med Interne; 2006 Jun; 27(6):473-7. PubMed ID: 16631280
[TBL] [Abstract][Full Text] [Related]
10. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
11. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera.
Silver RT
Leukemia; 2003 Jun; 17(6):1186-7. PubMed ID: 12764388
[No Abstract] [Full Text] [Related]
12. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
13. [Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].
Usui N; Miyamura K; Arai A; Motomura S; Yokoyama M
Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1434-55. PubMed ID: 17682432
[No Abstract] [Full Text] [Related]
14. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J
Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931
[TBL] [Abstract][Full Text] [Related]
15. Treatment of polycythemia vera with imatinib mesylate.
Silver RT; Bourla MH; Vandris K; Fruchtman S; Spivak JL; Feldman EJ; Salvado AJ
Leuk Res; 2012 Feb; 36(2):156-62. PubMed ID: 21983176
[TBL] [Abstract][Full Text] [Related]
16. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
[TBL] [Abstract][Full Text] [Related]
17. JAK2 inhibitors in polycythemia vera.
Quintás-Cardama A
Clin Adv Hematol Oncol; 2011 May; 9(5):397-400. PubMed ID: 21685869
[No Abstract] [Full Text] [Related]
18. Fatal hepatic necrosis following imatinib mesylate therapy.
Lin NU; Sarantopoulos S; Stone JR; Galinsky I; Stone RM; Deangelo DJ; Soiffer RJ
Blood; 2003 Nov; 102(9):3455-6. PubMed ID: 14568907
[No Abstract] [Full Text] [Related]
19. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
20. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
